

IN THE CLAIMS

1.-22. (canceled)

23. (currently amended) A product suitable for delivering a pharmaceutical aerosol formulation comprising,

(a) an aerosol canister comprising a container closed with a metering valve, said container comprising a pharmaceutical aerosol formulation substantially free of surfactant comprising,

(i) a bronchodilator selected from the group consisting of ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutaline, isoetharine, tolubuterol and orciprenaline, or a salt of said bronchodilator; and

(ii) a fluorocarbon propellant, wherein said bronchodilator is substantially completely insoluble in said fluorocarbon propellant; and

(iii) 610% w/w to 215% w/w of a polar co-solvent; and

(b) an actuator with a spray orifice aperture of from 100 to 300 microns.

24. (previously presented) The product of claim 23, wherein the bronchodilator is substantially insoluble in the co-solvent.

25. (previously presented) The product of claim 23, wherein the bronchodilator is in the form of a salt.

26. (previously presented) The product of claim 24, wherein the bronchodilator is in the form of a salt.

27. (canceled)

28. (canceled)

29. (previously presented) The product of claim 23, wherein the canister is actuated by a breath operated device.

30. (currently amended) The product of claim 23, wherein the propellant is 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n-propane.

31. (previously presented) The product of claim 23, wherein the bronchodilator is a salt of salbutamol.

32. (previously presented) The product of claim 31, wherein the propellant is 1,1,1,2-tetrafluoroethane.

33. (previously presented) The product of claim 31, wherein the polar co-solvent is ethanol.

34. (canceled)

35. (previously presented) The product of claim 31, wherein the propellant is 1,1,1,2-tetrafluoroethane and the polar co-solvent is ethanol.

36. (currently amended) The product of any of claims 31-3533 or 35, wherein the salt of salbutamol is salbutamol sulphate.

37. (canceled)

38. (previously presented) The product of claim 23, wherein the spray orifice aperture is from 150 to 250 microns.

39. (currently amended) A product suitable for delivering a pharmaceutical aerosol formulation comprising,

(a) an aerosol canister comprising a container closed with a metering valve, said container comprising a pharmaceutical suspension aerosol formulation substantially free of surfactant, and which comprises salbutamol sulphate, ethanol in an amount of 10% w/w to 15% w/w, and 1,1,1,2-tetrafluoroethane, wherein salbutamol sulphate is substantially completely insoluble in the 1,1,1,2-tetrafluoroethane, and

(b) an actuator with a spray orifice aperture of from 100 to 300 microns.

40. (previously presented) The product of claim 39, wherein the aerosol formulation contains salbutamol sulphate in the amount of 0.4% w/w.

41. (canceled)

42. (currently amended) The product of claim 4139, wherein the aerosol formulation contains ethanol in the amount of 11.4% w/w.

43. (previously presented) The product of claim 39, wherein the aerosol formulation contains 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

44. (previously presented) The product of claim 39, wherein the aerosol formulation contains salbutamol sulphate

in the amount of 0.4% w/w, ethanol in the amount of 11.4% w/w, and 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

45. (previously presented) The product of claim 39, wherein the spray orifice aperture is from 150 to 250 microns.

46. (previously presented) A product suitable for delivering a pharmaceutical aerosol formulation comprising,

(a) an aerosol canister comprising a container closed with a metering valve, said container comprising a pharmaceutical suspension aerosol formulation substantially free of surfactant, and which consists of salbutamol sulphate, ethanol, and 1,1,1,2-tetrafluoroethane, wherein salbutamol sulphate is substantially completely insoluble in the 1,1,1,2-tetrafluoroethane, and

(b) an actuator with a spray orifice aperture of from 100 to 300 microns.

47. (previously presented) A product suitable for delivering a pharmaceutical aerosol formulation comprising,

(a) an aerosol canister comprising a container closed with a metering valve, said container comprising a pharmaceutical suspension aerosol formulation substantially free of surfactant, and which consists essentially of salbutamol sulphate, ethanol, and 1,1,1,2-tetrafluoroethane, wherein the salbutamol sulphate is substantially completely insoluble in the 1,1,1,2-tetrafluoroethane, and

(b) an actuator with a spray orifice aperture of from 100 to 300 microns.